The Food and Drug Administration granted Neuralink an expanded approval for its brain-computer interface device on Thursday, extending the authorized patient population beyond the initial indication for individuals with severe paralysis to include those with a broader range of neurological conditions including locked-in syndrome, ALS, and certain forms of treatment-resistant depression.
What the Approval Covers
The expanded authorization allows implantation in approximately 850,000 additional patients annually who meet the newly defined eligibility criteria. The device, known as the N2, connects to the brain’s motor cortex via 1,024 electrodes and communicates wirelessly with external computing devices, allowing users to control computers, smartphones, and assistive technologies through thought alone.
Clinical Trial Data
The approval was based on safety and efficacy data from 341 patients who received the device in Neuralink’s pivotal trials. The primary efficacy endpoint — communication speed using the device — averaged 40 characters per minute for new users and 85 characters per minute for experienced users at the 12-month mark, compared to a baseline of zero for patients who could not communicate without the device.
The Enhancement Question
Regulators explicitly restricted the current approval to therapeutic use in patients with diagnosed neurological conditions. The question of whether BCIs could eventually be approved for use in otherwise healthy individuals seeking cognitive enhancement was raised at Thursday’s press conference — and pointedly not answered by agency officials.
Manufacturing Scale
Neuralink has announced the construction of a dedicated manufacturing facility with capacity for 10,000 surgical implantations annually, with plans to scale to 50,000 by 2029 pending continued regulatory clearance.
